Increase Height And Grow Taller Using Extracorporeal ShockWave Treatment, ESWT Part II

Me: I wanted to go deeper in the research for this method because it looks very promising as another tool. In my opinion, it might be better than LIPUS in helping achieve height increase.

From study 1…

The researchers tried the application of radial extracorporeal shock wave therapy (rESWT) to get bones to growth and form. There was 4000 impulses of the shock waves used on one of the hind legs of 13 rabbits. The other is not treated with rESWT as the control. after a week the shockwaves were doen again. What they found was that the rESWT significantly increase new bone formation at all time points throughout the study’s time period. It is interesting that the rate of bone formation was at the maximum at 4 weeks. The most amazing thing was the the location of the long bone which was closest to the shock wave application was where the most bone formation was found. It seems that the ESWT induced osteogenesis is dosage dependent. The best thing is that so trauma like hemmorhage or microfractures were found. The researchers conclude with “This is the first study demonstrating low-energy radial shock waves to induce new bone formation in vivo. Based on our results, repetition of ESWT in 6-week intervals can be recommended.

From study 2…

The researchers found that using ESWT was safe and a great alternative for fracture/ non union healing. It seemed to work better for tropic nonunions (with calluses) than atropic nonunions (without calluses). The study dosage is …”The shock waves were applied in 3-5 sessions of 2500 to 3000 impulses each given at 0.25-0.84 mJ/mm2, at intervals of 48-72 hours between sessions. A maximum of 3 cycles of treatment was given, at 3-month intervals.” The healing reduced the time needed for a large percentage but a smaller percentage did not see any healing.

From study 3...

This is another study which comfirms that ESWT is amazing. It has been used to heal achilles tendinitis and the researchers in this study wanted to shows that it heals the tendinitis by increasing the expression of TGF-Beta1 and IGF-1. The study varied the impulse dosage from 0, 200, 500, and 1000 impulses. The optimal dosage for the mice in the study was around 200 impulse at around 0.2 mJ/mm^2. Through out the entire study the expression of IGF-1 was elevated dramatically. It seems to show that cell proliferation, cell hypertrophy, and tissue regeneration were all effects. There was also a proliferation of tenocytes and neovascularization (new blood vessels).


From ScienceDirect.com study link HERE

Radial Extracorporeal Shock Wave Therapy (rESWT) Induces New Bone Formation in vivo: Results of an Animal Study in Rabbits

Abstract

The aim of this study was to investigate if radial extracorporeal shock wave therapy (rESWT) induces new bone formation and to study the time course of ESWT-induced osteogenesis. A total of 4000 impulses of radial shock waves (0.16 mJ/mm²) were applied to one hind leg of 13 New Zealand white rabbits with the contralateral side used for control. Treatment was repeated after 7 days. Fluorochrome sequence labeling of new bone formation was performed by subcutaneous injection of tetracycline, calcein green, alizarin red and calcein blue. Animals were sacrificed 2 weeks (n = 4), 4 weeks (n = 4) and 6 weeks (n = 5) after the first rESWT and bone sections were analyzed by fluorescence microscopy. Deposits of fluorochromes were classified and analyzed for significance with the Fisher exact test. rESWT significantly increased new bone formation at all time points over the 6-week study period. Intensity of ossification reached a peak after 4 weeks and declined at the end of the study. New bone formation was significantly higher and persisted longer at the ventral cortex, which was located in the direction to the shock wave device, compared with the dorsal cortex, emphasizing the dose-dependent process of ESWT-induced osteogenesis. No traumata, such as hemorrhage, periosteal detachment or microfractures, were observed by histologic and radiologic assessment. This is the first study demonstrating low-energy radial shock waves to induce new bone formation in vivo. Based on our results, repetition of ESWT in 6-week intervals can be recommended. Application to bone regions at increased fracture risk (e.g., in osteoporosis) are possible clinical indications.


From study 2 link HERE

Effects of Extracorporeal Shock Wave Therapy on Fracture Nonunions

Maria Chiara Vulpiani, MD, Mario Vetrano, MD, Federica Conforti, MD, Lucia Minutolo, MD, Donatella
Trischitta, MD, John P. Furia, MD, and Andrea Ferretti, MD

Abstract

The purpose of this study was to examine the effect of focused extracorporeal shock wave therapy (ESWT) on the treatment of nonunions. As part of a prospective study, we included 143 patients (average age, 41.4 years) with a diagnosis of nonunion (mean, 14.1 months; range, 6-84 months). High-energy shock wave treatment was applied using electromagnetic shock wave generators. The shock waves were applied in 3-5 sessions of
2500 to 3000 impulses each given at 0.25-0.84 mJ/mm2, at intervals of 48-72 hours between sessions. A maximum of 3 cycles of treatment was given, at 3-month intervals. The patients were followed during a 12-month period until fracture healing or, in case of failure, until another therapy was adopted. Complete healing was observed in 80 of 143 cases (55.9%) at an average time of 7.6 months (range, 2-24 months). Partial healing occurred in 41 cases (28.7%) and no healing was observed in 22 cases (15.4%). Patients with trophic nonunions had a better success rate than patients with atrophic nonunions (P<.05). The results show ESWT is a safe and effective treatment for nonunions. ESWT is more effective for trophic nonunions than atrophic nonunion


From the Journal Of Orthopaedic Research website study 3 link HERE

Extracorporeal shock waves promote healing of collagenase-induced Achilles tendinitis and increase TGF-b1 and IGF-I expression

Yeung-Jen Chen a, Ching-Jen Wang b, Kuender D. Yang c, Yur-Ren Kuo d, Hui-Chen Huang c, Yu-Ting Huang c, Yi-Chih Sun c, Feng-Sheng Wang
c,*

  • a Department of Orthopaedic Trauma, Chang Gung University, Linkou, Taiwan
  • b Department of Orthopedic Surgery, Chang Gung Memorial Hospital, Kaohsiung, Taiwan
  • c Department of Medical Research, Chang Gung Memorial Hospital, 123 Ta-Pei Road, Niao-Sung, Kaohsiung 833, Taiwan
  • d Department of Trauma, Chang Gung Memorial Hospital, Kaohsiung, Taiwan

Received 28 April 2003; accepted 20 October 2003

Abstract

Extracorporeal shock waves (ESW) have recently been used in resolving tendinitis. However, mechanisms by which ESW promote tendon repair is not fully understood. In this study, we reported that an optimal ESW treatment promoted healing of Achilles tendintis by inducing TGF-b1 and IGF-I. Rats with the collagenease-induced Achilles tendinitis were given a single ESW treatment (0.16 mJ/mm2 energy flux density) with 0, 200, 500 and 1000 impulses. Achilles tendons were subjected to biomechanical (load to failure and stiffness), biochemical properties (DNA, glycosaminoglycan and hydroxyproline content) and histological
assessment. ESW with 200 impulses restored biomechanical and biochemical characteristics of healing tendons 12 weeks after treatment. However, ESW treatments with 500 and 1000 impulses elicited inhibitory effects on tendinitis repair. Histological observation demonstrated that ESW treatment resolved edema, swelling, and inflammatory cell infiltration in injured tendons.  Lesion site underwent intensive tenocyte proliferation, neovascularization and progressive tendon tissue regeneration. Tenocytes at
the hypertrophied cellular tissue and newly developed tendon tissue expressed strong proliferating cell nuclear antigen (PCNA) after ESW treatment, suggesting that physical ESW could increase the mitogenic responses of tendons. Moreover, the proliferation of
tenocytes adjunct to hypertrophied cell aggregate and newly formed tendon tissue coincided with intensive TGF-b1 and IGF-I expression. Increasing TGF-b1 expression was noted in the early stage of tendon repair, and elevated IGF-I expression was persisted
throughout the healing period. Together, low-energy shock wave effectively promoted tendon healing. TGF-b1 and IGF-I played important roles in mediating ESW-stimulated cell proliferation and tissue regeneration of tendon.

 2003 Orthopaedic Research Society. Published by Elsevier Ltd. All rights reserved.

Increase Height And Grow Taller Using Extracorporeal ShockWave Treatment, ESWT (Important)

Me: For me this is quite possibly the biggest find I have encountered in a long time and a major breakthrough. I know that the LIPUS technology used low intensity pulsed sound waves but this approach is the exact opposite, which uses high intensity shockwaves to get bones to heal. The amount of research and information out there is very high and it’s application for bone remodeling is high as well.

From study 1

What we are seeing is that the ESWT technology has been around and acknowledged by medical professionals for at least 2 decades. This study shows that just like the PEMF and LIPUS technology, it can cause bone fractures or non-unions to heal together. The amount of high intensity pulsed wave is 6000 at 28kV in one session. A amall sample of blood was taken to test for NO level, TGF-Beta 1, VEGF, and BMP2, as well as calcium, alkaline phosphatase, calcitonin, and parathyroid hormone during 5 time zones, before the treatment, 1 day afterwards, and 1,3,and 6 months afterwards. In over 3/4th of the patients, there was union of the fracture. It seems that shockwaves caused an increase in the NO level and other osteogenic growth factors.

From study 2...

It seems that the ESWT technology has been used quite extensively in recent years as an alternative treatment from surgery. There are success in clinical and in vitro studies. The final conclusion…”FGF-2, an important growth factor in new bone formation, was shown to be produced by human fibroblasts and osteoblasts after treatment with ESWT. These findings demonstrate that ESWT is able to cause bone healing through a molecular way by inducing growth factor synthesis.

From study 3

Apparently the researchers have already looked into how to increase the long bong longitudinal growth rate by “We have studied several possibilities in order to stimulate longitudinal growth by means of enhancement of the vascular supply to the growth plate through perforations, implants or electromagnetic pulses.” So they looked into make a distraction, adding implants, and trying out E&M pulses like the PEMF technology. In this specific study it is stated…”we explored the effects of Extracorporeal Shockwave Therapy (ESWT) in the same animal model, to determine a possible longitudinal bone growth stimulation“. This is huge!! It is almost very much like the noninvasive electrical device patent we looked at a month back. The performed it on 24 rabbits putting the ESW stimulation on the tibia and femur using both a mid level pulse and a high level pulse. The left limbs were treated with 2000 pulses. There doesn’t seem to be any differences in cell count, fracture formation, periosteal reaction. However the longitudinal increase was 4.1% on average for all the limbs.


From PubMed study 1 link HERE

Nitric Oxide. 2009 Jun;20(4):298-303. Epub 2009 Mar 10.

The effects of shockwave on bone healing and systemic concentrations of nitric oxide (NO), TGF-beta1, VEGF and BMP-2 in long bone non-unions.

Wang CJ, Yang KD, Ko JY, Huang CC, Huang HY, Wang FS.

Source

Department of Orthopedic Surgery, Chang Gung University College of Medicine, Chang Gung Memorial Hospital-Kaohsiung Medical Center, Taiwan.

Abstract

This study investigated the effects of extracorporeal shockwave treatment (ESWT) on bone healing and the systemic concentrations of nitric oxide (NO), TGF-beta1, VEGF and BMP-2 in long bone non-unions. Forty-two patients with 42 established non-unions of the femur and tibia were enrolled in this study. Each long bone non-union was treated with 6000 impulses of shockwave at 28 kV in a single session. Ten milliliters of peripheral blood were obtained for measurements of serum NO level and osteogenic growth factors including TGF-beta1, VEGF and BMP-2; serum levels of calcium, alkaline phosphatase, calcitonin and parathyroid hormone before treatment and at 1 day, 1, 3 and 6 months after treatment. The evaluations for bone healing included clinical assessments and serial radiographic examinations. At 6 months, bony union was radiographically confirmed in 78.6%, and persistent non-union in 21.4%. Patients with bony union showed significantly higher serum NO level, TGF-beta1, VEGF and BMP-2 at 1 month after treatment as compared to patients with persistent non-union. Shockwave-promoted bone healing was associated with significant increases in serum NO level and osteogenic growth factors. The elevations of systemic concentration of NO level and the osteogenic factors may reflect a local stimulation of shockwave in bone healing in long bone non-unions.

PMID:  19281856      [PubMed – indexed for MEDLINE]

From study 2 link HERE

Archives of Orthopaedic and Trauma Surgery
March 2011, Volume 131, Issue 3, pp 303-309

Stimulation of bone growth factor synthesis in human osteoblasts and fibroblasts after extracorporeal shock wave application

  • Joerg Hausdorf, Birte Sievers, Marcus Schmitt-Sody, Volkmar Jansson, Markus Maier, Susanne Mayer-Wagner

Abstract

Background

Nonunion is a common problem in Orthopedic Surgery. In the recent years alternatives to the standard surgical procedures were tested clinically and in vitro. Extracorporeal shock wave therapy (ESWT) showed promising results in both settings. We hypothesized that in target tissue cells from nonunions like fibroblasts and osteoblasts ESWT increases the release of bone growth factors.

Methods

Fibroblasts and osteoblasts were suspended in 3 ml cryotubes and subjected to 250/500 shock waves at 25 kV using an experimental electrohydraulic lithotripter. After ESWT, cell viability was determined and cells were seeded at 1 × 105 cells in 12 well plates. After 24, 48, and 72 h cell number was determined and supernatant was frozen. The levels of growth factors FGF-2 and TGF-β1 were examined using ELISA. A control group was treated equally without receiving ESWT.

Results

After 24 h there was a significant increase in FGF-2 levels (p < 0.05) with significant correlation to the number of impulses (p < 0.05) observed. TGF-β1 showed a time-dependent increase with a peak at 48 h which was not significantly different from the control group.

Conclusions

FGF-2, an important growth factor in new bone formation, was shown to be produced by human fibroblasts and osteoblasts after treatment with ESWT. These findings demonstrate that ESWT is able to cause bone healing through a molecular way by inducing growth factor synthesis.


From ISMST.com study 3 link HERE

Bone Growth Stimulation with Extracorporeal Shockwaves – Experimental Animal Model

Authors: Carlos Leal, Juan C. Lopez, Oscar E. Reyes

Institution:

Orthopaedic Research Laboratory, Bosque University Orthopaedics Program, Bogota DC, Colombia

Discrepancy in limb lengths is a common orthopaedic problem arising from either shortening or overgrowth of one or more bones of the limb. Minor discrepancies due to assimetry are very common, and these differences under 20 mm are well compensated, being almost one third of the normal asimptomatic population. Differences between 20 and 50 mm cause biomechanical problems in gait, spine deformities and early osteoarthrosis due to limb malalignement. However, these discrepancies are too small to consider major surgical procedures such as lengthenings, osteotomies or epiphisiodesis. We have studied several possibilities in order to stimulate longitudinal growth by means of enhancement of the vascular supply to the growth plate through perforations, implants or electromagnetic pulses.

In the present study we explored the effects of Extracorporeal Shockwave Therapy (ESWT) in the same animal model, to determine a possible longitudinal bone growth stimulation. We based our study in the literature reports that show femoral overgrowth after shaft fractures in children. Even though this side effect has been reported by many authors like Aitken in 1940, Shapiro in 1981 and Murray in 1996, the precise mechanism of vascular and humoral stimulation is still unknown. The microfractures caused by ESWT could generate the same effects and produce longitudinal overgrowth.

We studied 24 NewZealand Rabbits of 2 months of age and 2 Kg of weight, performind ESWT stimulation on tibial and femoral shafts. The specimens were divided in two groups: One using mid level ESWT (0.2 mj/mm2) and one using high level ESWT (0.5 mj/mm2). We treated the left limbs with 2000 shockwaves under sedation, and used the contralateral femurs and tibias as controls. The specimens were followed for 12 weeks, and after sacrifice longitudinal measurements were performed with milimetrical gauges. We also studied the X Rays on every specimen in order to describe any pathological finding, and performed a histomorphometric analysis to measure celularity and vascular patterns.

Our results showed that all femurs and tibias treated with ESWT grew more than their contralateral controls, but no statistically significant differences were found in the 2 way anova analysis comparing groups (P>0.05).No radiological differences were found, and the blind analysis did not show signs of periosteal reaction, macroscopic fractures or physeal changes.

The histomorphometric analysis did not show any differences in cell counts, physeal size or vascular patterns between groups. A normalized analysis was performed in order to determine the amount of growth comparing the differences between treated bones and their contralateral controls. We found that the overall growth was of 4.11% in average for femurs, tibias and whole limbs. Our results showed a very significant effect of ESWT on growing bone, in all of our treated specimens. However the comparison between groups is not significant, probably due to biological variability. We need to validate the overgrowth effect in terms of histologic and biologic ethiology, and current studies that include bone scanning and molecular biology are being performed to determine the precise cause of this ESWT growth stimulation.

A Study On Hypogonadotropic Hypogonadism And Hypergonadotropic Hypogonadism

Me: When I was doing research on the effects of  combining Gonadotropin releasing hormone analogues (GnRH-A) with human growth hormones (hGH) as a way to treat the many diverse forms of short stature, this very interesting disorder really caught my attention and I wanted to devote some time to learn more about this disorder since it might help us remove some confusion over certain issues. We know that the control and flow of the sex hormones is what can ultimately determine out final height since we have already seen how certain people without the right types of hormones or hormone receptors never even reach puberty or don’t have closed growth plates resulting in continued growth even into their 30s.

Analysis & Interpretation:

There is two main conditions we are finding with very similar names, except that one process is the opposite of the other. One is called Hypogonadotropic Hypogonadism and the other is called Hypergonadotropic Hypogonadism. The prefix “hyper” has always meant “excessive” in common english terms while the prefix “hypo” means “not enough” in common english terms. From the two Wikipedia articles I have posted below, the summarize idea is that HH and HH, the hyper and the hypo, both results in hypogonadism, which is where the body doesn’t get enough hormones from the gonads, the reproductive organs. The hypogonadotropic hypogonadism sees an impaired secretion of the gonadotropins like the FSH and LH by the pituitary gland and the hypothalamus of the brain. Since the endocrine system works from a top–>down approach, this will eventually lead to less sex hormones produced in the gonads of the person. The is why the 2nd term is hypogonadism.

The hypergonadotropic hypogonadism in comparison has the pituitary gland and the hypothalamus being just fine in function and releasing the neccessary amount of gonadotropins like the FSH and the LH but the problem is that the gonads can’t seem to be able to receive the gonadotropins or can’t process them correctly to release the high enough levels of gonad hormones, like the androgen and estrogen. The symptoms of hypogonadism in general is low sex drive, infertility, and not puberty signs like hair growth, etc. To treat the first type, where the brain areas don’t release enough, physicians can directly add the needed hormones using a GnRH agonist or a gonadotropin formulation. To treat the 2nd type, the physician can just add synthetic androgens as a hormone therapy to get the level of sex hormones in the body correct.

The connection with height increase with the two conditions is that from many genetic disorders and cases, we find that people who have no sensitivity to the sex hormones like the androgens or estrogen have often led to delayed puberty, and thus resulted in a later age for growth plate cartilage closure. There are at least 3 cases of males who had no receptors for the estrogen in their growth plates and they resulted in being very tall with the cartilage still existing in late adulthood.

From my personal analysis, it would seem that the case for tall stature can only be found with people who suffer from hypergonadotropic hypogonadism, NOT hypogonadotropic hypogonadism.  I would guess that the lack of ability to release the FSH and the LP by the hypothalamic-pituitary connection would also cause insufficient release of the growth hormones too. So it would make logical sense then that the human body which can release growth hormones but stop the process of reeleasing the testosterone and estrogens which will lead to both puberty/increased growth rate but also growth plate closure means that the person who suffers only from hypergonadotropic hypogonadism will note that they never went through the great growth spurt that their peers did in adolescent, noticed that they were more likely on the short side while young, but as they grew older, they did not stop growing completely like their peers but eventually surpasses in height of their peers in their late 20s due to their open growth plate cartilage.


From the Wikipedia article on it HERE

Hypogonadotropic hypogonadism (HH), also known as secondary or central hypogonadism, as well as gonadotropin-releasing hormone deficiency or gonadotropin deficiency (GD), is a condition which is characterized by hypogonadism due to an impaired secretion of gonadotropins, including follicle-stimulating hormone (FSH) and luteinizing hormone (LH), by the pituitary gland in the brain, and in turn decreased gonadotropin levels and a resultant lack of sex steroid production.

Causes

The type of HH, based on its cause, may be classified as either primary or secondaryPrimary HH, also called isolated HH, is responsible for only a small subset of cases of HH, and is characterized by an otherwise normal function and anatomy of the hypothalamus and anterior pituitary. It is caused by congenital syndromes such as Kallmann syndrome and gonadotropin-releasing hormone (GnRH) insensitivity. Secondary HH, also known as acquired or syndromic HH, is far more common than primary HH, and is responsible for most cases of the condition. It has a multitude of different causes, including brain orpituitary tumors, pituitary apoplexy, head trauma, ingestion of certain drugs, and certain systemic diseases and syndromes.

Symptoms

Examples of symptoms of hypogonadism include delayed, reduced, or absent puberty, low libido, and infertility.

Treatment

Treatment of HH may consist of administration of either a GnRH agonist or a gonadotropin formulation in the case of primary HH and treatment of the root cause (e.g., a tumor) of the symptoms in the case of secondary HH. Alternatively, hormone replacement therapy with androgens and estrogens in males and females, respectively, may be employed.


Now let’s look at the opposite of it which is termed Hypergonadotropic Hypogonadism

From the Wikipedia article on it HERE

Hypergonadotropic hypogonadism (HH), also known as primary or peripheral/gonadal hypogonadism, is a condition which is characterized by hypogonadism due to an impaired response of the gonads to the gonadotropins, follicle-stimulating hormone (FSH) and luteinizing hormone (LH), and in turn a lack of sex steroid production and elevated gonadotropin levels (as an attempt of compensation by the body). HH may present as either congenital or acquired, but the majority of cases are of the former nature.

Causes

  • Chromosomal abnormalities (resulting in gonadal dysgenesis) – Turner’s syndrome, Klinefelter’s syndrome, Swyer’s syndrome, XX gonadal dysgenesis, and mosaicism.
  • Defects in the enzymes involved in the gonadal biosynthesis of the sex hormones – 17α-hydroxylase deficiency, 17,20-lyase deficiency, 17β-hydroxysteroid dehydrogenase III deficiency, and lipoid congenital adrenal hyperplasia.
  • Gonadotropin resistance (e.g., due to inactivating mutations in the gonadotropin receptors) – Leydig cell hypoplasia (or insensitivity to LH) in males, FSH insensitivity in females, and LH and FSH resistance due to mutations in the GNAS gene (termed pseudohypoparathyroidism type 1A).

Acquired causes (due to damage to or dysfunction of the gonads) include gonadal torsion, vanishing/anorchia, orchitis, premature ovarian failure, ovarian resistance syndrome, trauma, surgery, autoimmunity,chemotherapy, radiation, infections (e.g., sexually-transmitted diseases), toxins (e.g., endocrine disruptors), and drugs (e.g., antiandrogens, opioids, alcohol).

Symptoms

Examples of symptoms of hypogonadism include delayed, reduced, or absent puberty, low libido, and infertility.

Treatment

Treatment of HH is usually with hormone replacement therapy, consisting of androgen and estrogen administration in males and females, respectively.

Axial Tibial Compression Stimulated A Robust Endocortical And Periosteal Bone-Formation Response, Maybe LSJL Works?

Me: This study is one of those studies which make me believe that the LSJL method may actually indeed work in causing some form of long bone lengthening. Sure, there are some obvious clear differences between the two ideas. The biggest one is that while this study involved axial compression on the long bone, the LSJL loading method involved loading and compression in a lateral direction. Right off the bat the researchers admit that with again, the skeleton lose its ability to respond to mechanical stimuli, so at least they get that quick rebuttal in theory arguement taken care of. They are hypothesizing that the loading would be less responsive but we already know that (so why are they doing this experiment??). From both the aged and young mice, if we load on the mid diaphysis area of the long bones, there is an analbolic response from the periosteal side (outside layer) and the endocortical side (inside layer). They say that with increase peak force, the bone formation was higher. Apparently aged mice had a far bigger response to the loading than young mice at least for the endocortical (inside) layer which surprised the researchers. The results…”Responses at the periosteal surface did not differ between age groups (p > .05). The loading-induced increase in bone formation resulted in increased cortical area in both age groups (loaded versus control, p < .05).”  They conclude with..”In summary, 1 week of daily tibial compression stimulated a robust endocortical and periosteal bone-formation response at the mid-diaphysis in both young-adult and aged male BALB/c mice. We conclude that aging does not limit the short-term anabolic response of cortical bone to mechanical stimulation in our animal model.

Implications: This does make me wonder whether LSJL might really do work since we can use a thought experiment (like how einstein used to do). Let’s imagine that the long bone is surrounding by some thicker layer of cortical bone even in the epiphysis. If the compression at a axial direction on the middle diaphysis area results in the same rate of periosteal growth in both aged and young mice, then the compression of the epiphysis may actually in crease bone lengthening because the periosteum wraps around the entire long bone and even underneath the articular cartilage of the. The loading of the epiphysis would lead the bones to react by causing the peristeal layer to grow appositionally on the epiphysis which means that the axial ends do indeed get thicker and thicker which means the bones really do get longer so height is increased. Age seems to have no effect in decreased bone sensitivity, at least for the initial beginning loading. It might be that what you do from the beginning of LSJL program is what can result in the most bone/ periosteal growth lengthening, or at least until you might stop doing it for a while and go back to it a few weeks later allowing for the bone sensitivity to come back, if it ever truly do. 


From PubMed study link HERE

J Bone Miner Res. 2010 Sep;25(9):2006-15.

Aged mice have enhanced endocortical response and normal periosteal response compared with young-adult mice following 1 week of axial tibial compression.

Brodt MD, Silva MJ.

Source

Department of Orthopaedic Surgery, Washington University, School of Medicine, St Louis, MO 63110, USA.

Abstract

With aging, the skeleton may lose its ability to respond to positive mechanical stimuli. We hypothesized that aged mice are less responsive to loading than young-adult mice. We subjected aged (22 months) and young-adult (7 months) BALB/c male mice to daily bouts of axial tibial compression for 1 week and evaluated cortical and trabecular responses using micro-computed tomography (µCT) and dynamic histomorphometry. The right legs of 95 mice were loaded for 60 rest-inserted cycles per day to 8, 10, or 12 N peak force (generating mid-diaphyseal strains of 900 to 1900 µε endocortically and 1400 to 3100 µε periosteally). At the mid-diaphysis, mice from both age groups showed a strong anabolic response on the endocortex (Ec) and periosteum (Ps) [Ec.MS/BS and Ps.MS/BS: loaded (right) versus control (left), p < .05]. Generally, bone formation increased with increasing peak force. At the endocortical surface, contrary to our hypothesis, aged mice had a significantly greater response to loading than young-adult mice (Ec.MS/BS and Ec.BFR/BS: 22 months versus 7 months, p < .001). Responses at the periosteal surface did not differ between age groups (p > .05). The loading-induced increase in bone formation resulted in increased cortical area in both age groups (loaded versus control, p < .05). In contrast to the strong cortical response, loading only weakly stimulated trabecular bone formation. Serial (in vivo) µCT examinations at the proximal metaphysis revealed that loading caused a loss of trabecular bone in 7-month-old mice, whereas it appeared to prevent bone loss in 22-month-old mice. In summary, 1 week of daily tibial compression stimulated a robust endocortical and periosteal bone-formation response at the mid-diaphysis in both young-adult and aged male BALB/c mice. We conclude that aging does not limit the short-term anabolic response of cortical bone to mechanical stimulation in our animal model.

© 2010 American Society for Bone and Mineral Research.

PMID: 20499381  [PubMed – indexed for MEDLINE] 
PMCID:  PMC3153404

Increase Height And Grow Taller Using Indian Aryuveda Homeopathic Medicine Capsules (Interesting)

This is something which I found today while I was going around the internet checking links. It is from a site HerbalCureIndia.Com. What is really interesting is that this webpage actually provides a height increase compound mixture which is really surprising. What I wanted to do is maybe go through this list and see what are the English, or scientific, or chemical names for these compounds. This is a list of minerals and plants you combine their extracts together to form a height increasing aryuveda homeopathic medicine capsule.

Ingredients

  • Withinia somniferra 75 mg
  • Puraria tuberose 75 mg
  • Lepidium sativum 150 mg
  • Gentiana sativum 150 mg
  • Acacia Arabica 50 mg
  • Ephedra gerardiana 5 mg
  • Cassia tora 30 mg
  • Oroxylum indicum 30 mg
  • Mucana pruries 50 mg
  • Cassytha filiformis 10 mg
  • Lauh bhasam 10 mg

One thing that has already caught my eye is the mucana pruries which I have looked into before (velvet beans) which does have a link to extra HGH release and L-Dopa. It should be spelled actually Mucuna pruriens. From the wikipedia article on the pruriens HERE

Pharmacology

M.pruriens seeds contain high concentrations of levodopa, a direct precursor of the neurotransmitter dopamine. It has long been used in traditional Ayurvedic Indian medicine for diseases includingParkinson’s disease. In large amounts (e.g. 30 g dose), it has been shown to be as effective as pure levodopa/carbidopa in the treatment of Parkinson’s disease, but no data on long-term efficacy and tolerability are available.

In addition to levodopa, it contains serotonin (5-HT), 5-HTP, nicotine, N,N-DMT (DMT), bufotenine, and 5-MeO-DMT. As such, it could potentially have psychedelic effects, and it has purportedly been used in ayahuasca preparations.

The mature seeds of the plant contain about 3.1-6.1% L-DOPA, with trace amounts of 5-hydroxytryptamine (serotonin), nicotine, DMT-n-oxide, bufotenine, 5-MeO-DMT-n-oxide, and beta-carboline. One study using 36 samples of the seeds found no tryptamines present in them.

The leaves contain about 0.5% L-DOPA, 0.006% dimethyltryptamine (DMT), 0.0025% 5-MeO-DMT and 0.003% DMT n-oxide. The ethanolic extract of leaves of Mucuna pruriens possesses anticataleptic and antiepileptic effect in albino rats. Dopamine and serotonin may have a role in such activity.

Me: This is the actual ingredients of the capsule which is very interesting! If I even do a quick search on the first plant/mineral on the list Withinia somniferra, it turns up a PubMed study (link HERE). Another name for it is ashwagandha. From another study (source HERE) it seems that ashwagandha can reverse Alzheimer’s Disease Pathology suggesting it does it by enhancing low-density lipoprotein receptor-related protein in liver


Altern Med Rev. 2000 Aug;5(4):334-46.

Scientific basis for the therapeutic use of Withania somnifera (ashwagandha): a review.

Mishra LC, Singh BB, Dagenais S.

Source

Los Angeles College of Chiropractic (LACC), 16200 E Amber Valley Dr., Whittier, CA 90609-1166. lakshmimishra@lacc.edu

Abstract

OBJECTIVE:

The objective of this paper is to review the literature regarding Withania somnifera (ashwagandha, WS) a commonly used herb in Ayurvedic medicine. Specifically, the literature was reviewed for articles pertaining to chemical properties, therapeutic benefits, and toxicity.

DESIGN:

This review is in a narrative format and consists of all publications relevant to ashwagandha that were identified by the authors through a systematic search of major computerized medical databases; no statistical pooling of results or evaluation of the quality of the studies was performed due to the widely different methods employed by each study.

RESULTS:

Studies indicate ashwagandha possesses anti-inflammatory, antitumor, antistress, antioxidant, immunomodulatory, hemopoietic, and rejuvenating properties. It also appears to exert a positive influence on the endocrine, cardiopulmonary, and central nervous systems. The mechanisms of action for these properties are not fully understood. Toxicity studies reveal that ashwagandha appears to be a safe compound.

CONCLUSION:

Preliminary studies have found various constituents of ashwagandha exhibit a variety of therapeutic effects with little or no associated toxicity. These results are very encouraging and indicate this herb should be studied more extensively to confirm these results and reveal other potential therapeutic effects. Clinical trials using ashwagandha for a variety of conditions should also be conducted.

PMID: 10956379  [PubMed – indexed for MEDLINE]       Free full text

Me: What is below is from the webpage which is linked above.

Increase your Height Growth Naturally

Height increasing capsules
To increase height and growth
Products Qty Sale Price Order Now
60 Capsules $35  
120 Capsules $65.99 
180 Capsules $80

Dosage & Uses:
10-12 yrs – one capsule each twice a day.
13-21 yrs – two capsule twice a day.
22-25 yrs – two capsule thrice a day

For Shipping in india.

120 Capsules : Rs 650/- + Rs. 199/- for Shipping, Handling and Processing Charges, Services

Total : Rs.849/- for 120 Capsules

The height increasing capsules. The most talked about herbal supplemst based on the guidelines of ayurveda. It not only inceses your height but alo makes you look taller, smater and confident. Enpowerd with the active herbals, Height Increasing Capsules will make you taller and confident, the condition you only dreamth of.

Ingredients

  • Withinia somniferra 75 mg
  • Puraria tuberose 75 mg
  • Lepidium sativum 150 mg
  • Gentiana sativum 150 mg
  • Acacia Arabica 50 mg
  • Ephedra gerardiana 5 mg
  • Cassia tora 30 mg
  • Oroxylum indicum 30 mg
  • Mucana pruries 50 mg
  • Cassytha filiformis 10 mg
  • Lauh bhasam 10 mg

Height Increasing Capsules is one of the solution that helps in stimulating the human growth hormone that will help you in gaining the height. Human growth hormone is secreted from the anterior aspect of the pituitary gland (the master gland) situated in the brain. Production of growth hormone is at the highest in the teens (13 to 19 years of age) and this is the time maximum people attain their height and growth. But growth hormone secretions drastically falls after this age and the growth stops.

Height Increasing Capsules is useful at this stage. Due to the active herbal formulations it stimulates the anterior part of pituitary gland that in turn secretes the growth hormone that is very effective in promoting growth and height of an individual when the secretion of the growth hormone ceases.

Height Increasing Capsules helps in maintaining the normal bodies chemical constituency and also rejuvenate the bodies cells, which are the two main reason by which the human body achieves growth. Height Increasing Capsules initiate the bones of the body to grow bigger and stronger while it accelerates the transformation of excess fats into energy. In other words, if the growth hormone secretion increases, your body gets stimulation to increase height and growth.

Forget the very dangerous and riskful growth hormone injection or limb lengthening operation. They are too costly and unsafe and extremely harmful to the body in long run. What you need is a safe, effective and with in reach of your pocket. Grow taller in the most natural and effective way.

As per the human growth medical research of Dr Ichiro Kawaguchi of Tokyo Research Laboratory of the National Health Department and Dr A. Kawata from the Kyoto University, height is not indomitable by genetic structure alone but is strongly inclined by the effects of specific hormones on the enlargement of the 26 skeletal bones and the cartilages of the 62 bones of the lower portion of the body. The excitement of the pituitary gland that will increase secretion of growth hormonal that will initiate the growth of the cartilaginous portions of the bones of the lower body, eventually leading to height increase.

Rigorous scientific research has proven that most young adults can still grow a few inches taller even after the bones in their lower body have turn into bony tissue (commonly known as “bone plate is fused”). This is because in addition to the length of the femur bone (thighbone), shinbone, and other bones in the lower body, the length of the spinal column in the upper body also significantly addto human height (about 35% of the total height).

Anatomically human spinal cord consists of 33 bone segments known as vertebrae detained together by ligaments (tough and fibrous tissue). Out of these 33 vertebrae, only the lowest 9 vertebrae are merged into two immovable bones, the sacrum and the coccyx, forming the back of the pelvis. All the other 24 vertebrae are enduringly movable and thus will never get fused (until some deformity). These 24 vertebrae are the 7 cervical (neck), 12 thoracic (back of chest), and 5 lumbar (loin).

Situated between each of these twenty four vertebrae bones are cartilage pads known as disks . The thickness of the disks establishes the length of the spinal cord and unswervingly influencing the height. There are totally twenty five such disks, their mutual length accounts twenty five percent of the total height. As these disks never fuse, they continuously grow thicIncrease your heightker under the spur of growth hormone all our life. 

The thicker these disks are, the longer the spinal cord is and the taller you grow. Even each disk grows only 0.25 cm thicker, that means you will grow 0.25 * 25 = 6.25 cm i.e. 2.5 inches taller! Wow….. that’s amazing.

In addition providing you the extra centimeters you always desired, you has been proven to boost blood circulation, improve digestion, augment metabolism, decrease tiredness, retard aging, regularizes breathing and promote general good health. Truly Height Increasing Capsulesis the fantastic way to grow taller and remain healthy at the same time!

Increase your height the best way without any side effects and at the lowest prise ever.

Recent Questions

Is there any herbal Supplement To Increase Height?

I am a 15 years old female. I have come across lots and lots of pills that claim to increase height. But most of them are scams. So hopefully in this website, I can find something that really works. Thanks!. Dovey, Toronto, Canada

Answer – Hello Dovey, Before going to any medication, one should understand the basics behind low height of an individual. The first and foremost reason of low height is nutritional deficiency and mal nutrition in the body. If a person is not consuming nutritive food of optimum grade in the right levels, he or she may fall prey to poor growth. This eventually affects the growth hormone activity in the body.

Hence the first conclusion is that you should start taking right diet and ample amount of nutritive food that will support you in stimulating your growth hormone gland to make you tall. Secondly we have a wonderful herbal supplement known as Height Increasing Capsules. Speed Height Capsules are enriched with some of the very rare and effective herbs that are known to increase height.

Even researches have also proved that Speed Height Capsules not only helps in increasing the height but also are very effective in balancing the height to weight ration in the body so that you would look appropriate body wise. Hence you should not wait and get one pack of Speed Height Capsules. I recommend you to take these capsules for at least 3 to 6 months for best results.

 

 

Injecting Fibroblast Growth Factor FGF Into Fracture Sites From Distraction

Me: These types of studies are really the best type for us to see how they would effect the bones. From the 1st study, we see that from just adding 1 microgram of aFGF either every other day or every day we can get larger callus size, greater collagen content, more DNAm and also soft cartilagous callus. The calluses for the aFGF injected are bigger for at least 4 weeks until it was taken over by trabecular bone. However there was evidence from the histological testing that the mRNA expression for certain types of procollagen was lower.

From study three, we have just one injection of 100 microgram of basic FGF (bFGF) which increases the Collagen Type X and Type II mRNA expression (in hypertrophic and proliferative chondroctyes respectively) and increase the proliferation of chondroprogenitor cells in fracture callus, and thus contributes to the formation of a larger cartilage. This does not cause the ossification and maturation of the chondrocytes though. The healing process has not been decreased. In terms of height increase, this is a fascinating growth factor because it does not cause the ossification to overcome the new chondrocytes too quickly. Since maturation and ossification is the irriversible proess hypertrophic chondrocytes turn into the eventual bone, what we should be doing is maximizing the number of chondrocytes but also delaying the time of maturation. 

From study two, we have the experiment repeated with one injection of 100 microgram of bFGF encapsulated in 200 microliter of fibrin gel. The results and evaluated parameters of the bone union rate, bone mineral density (BMD), and mechanical properties (strength and stiffness) of the callus was no different between the control group and the FGF injected group. the mRNA expression was also not changed much between the two groups. Again, the author states that the FGF makes the callus from the distraction larger but the healing process is not accelerated. 

From PubMed study link HERE

J Orthop Res. 1990 May;8(3):364-71.

Acidic fibroblast growth factor (aFGF) injection stimulates cartilage enlargement and inhibits cartilage gene expression in rat fracture healing.

Jingushi S, Heydemann A, Kana SK, Macey LR, Bolander ME.

Source

Orthopaedic Research Unit, NIAMS, NIH, Bethesda, MD 20892.

Abstract

The effect of the administration of acidic fibroblast growth factor (aFGF) on normal fracture healing was examined in a rat fracture model. One microgram of aFGF was injected into the fracture site between the first and the ninth day after fracture either every other day or every day. aFGF-injected calluses were significantly larger than control calluses, although this does not imply an increased mechanical strength of the callus. Histology showed a marked increase in the size of the cartilaginous soft callus. Total DNA and collagen content in the cartilaginous portion of the aFGF-injected calluses were greater than those of controls, although the collagen content/DNA content ratio was not different between the aFGF-injected and control calluses. Fracture calluses injected with aFGF remained larger than controls until 4 weeks after fracture. The enlarged cartilaginous portion of the aFGF-injected calluses seen at 10 days after fracture was replaced by trabecular bone at 3 and 4 weeks. Northern blot analysis of total cellular RNA extracted separately from the cartilaginous soft callus and the bony hard callus showed decreased expression of type II procollagen and proteoglycan core protein mRNA in the aFGF-injected calluses when compared with controls. A slight decrease in types I and III procollagen mRNA expression was also observed. We concluded that aFGF injections induced cartilage enlargement and decreased mRNA expression for type II procollagen and proteoglycan core protein.

PMID:  2324855     [PubMed – indexed for MEDLINE]

From PubMed study link HERE 

Calcif Tissue Int. 2007 Aug;81(2):132-8. Epub 2007 Jul 19.

Effects of a single percutaneous injection of basic fibroblast growth factor on the healing of a closed femoral shaft fracture in the rat.

Nakajima F, Nakajima A, Ogasawara A, Moriya H, Yamazaki M.

Source

Department of Orthopedic Surgery, Chiba University Graduate School of Medicine, 1-8-1 Inohana, Chuo-ku, Chiba, 260-8677, Japan.

Abstract

Recently, bioactive agents to stimulate bone formation have been available in the orthopedic field. We have shown previously that a single, local injection of basic fibroblast growth factor (bFGF) contributes to the formation of a larger cartilage (soft callus) but does not promote replacement of the cartilage by osseous tissue during experimental closed femoral fracture healing. Aiming at a clinical application, the present study was undertaken to clarify the effects of locally injected bFGF on bone (hard callus) formation and the mechanical properties of the callus in closed fracture healing in rats. Immediately after fracture, a carrier (200 muL of fibrin gel) containing 100 mug of bFGF or carrier alone was applied to the fracture site. At days 42 and 56 postfracture, the bone union rate, bone mineral density (BMD), and mechanical properties (strength and stiffness) of the callus were evaluated. Unexpectedly, with the exception of reduced stiffness in the FGF-injected callus at day 56, none of these parameters showed a significant difference between the control and the FGF-injected groups. Furthermore, the temporal expression pattern of OPN mRNA during healing was very similar between groups. We conclude that, in the healing of closed fractures of long bones, administration of bFGF forms a larger callus but does not necessarily accelerate the healing process.

PMID:   17638037    [PubMed – indexed for MEDLINE]

From PubMed study link HERE

J Orthop Res. 2001 Sep;19(5):935-44.

Spatial and temporal gene expression in chondrogenesis during fracture healing and the effects of basic fibroblast growth factor.

Nakajima F, Ogasawara A, Goto K, Moriya H, Ninomiya Y, Einhorn TA, Yamazaki M.

Source

Department of Orthopaedic Surgery, Chiba University School of Medicine, Japan.

Abstract

Chondrogenesis is an essential component of endochondral fracture healing, though the molecular and cellular events by which it is regulated have not been fully elucidated. In this study, we used a rat model of closed fracture healing to determine the spatial and temporal expression of genes for cartilage-specific collagens. Furthermore, to determine the effects of basic fibroblast growth factor (bFGF) on chondrogenesis in fracture healing, we injected 100 microg recombinant human bFGF into the fracture site immediately after fracture. In normal calluses, pro-alpha1(II) collagen mRNA (COL2A1) was detected in proliferative chondrocytes beginning on day 4 after the fracture, and pro-alpha1(X) collagen mRNA (COL10A1) in hypertrophic chondrocytes beginning on day 7. In FGF-injected calluses, the cartilage enlarged in size significantly. On day 14, both COL2A1- and COL10A1-expressing cells were more widely distributed, and the amounts of COL2A1 and COL10A1 mRNAs were both approximately 2-fold increased when compared with uninjected fractures. Temporal patterns of expression for these genes were, however, identical to those found in normal calluses. The number of proliferating cell nuclear antigen-positive cells was increased in the non-cartilaginous area in the bFGF-injected calluses by day 4. The present molecular analyses demonstrate that a single injection of bFGF enhances the proliferation of chondroprogenitor cells in fracture callus, and thus contributes to the formation of a larger cartilage. However, maturation of chondrocytes and replacement of the cartilage by osseous tissue are not enhanced by exogenous bFGF, and this results in the prolonged cartilaginous callus phase. We conclude that, in the healing of closed fractures of long bones, exogenous bFGF has a capacity to enlarge the cartilaginous calluses, but not to induce more rapid healing.

PMID:  11562144      [PubMed – indexed for MEDLINE]